Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299965 | 1.00 | SLC18A3 (0.44) | SLC18A3CHRM3TRPV1ACHECHRM2 | |
| SCHEMBL205316 | 1.00 | SLC18A3 (0.44) | SLC18A3CHRM3TRPV1ACHECHRM2 | |
| Bromide SCHEMBL23045101 | 0.98 | SLC18A3 (0.43) | SLC18A3CHRM3TRPV1ACHECHRM2 | |
| Bromide SCHEMBL23045102 | 0.98 | SLC18A3 (0.43) | SLC18A3CHRM3TRPV1ACHECHRM2 | |
| Alcohol SCHEMBL2321849 | 0.92 | HTR1A (0.43) | — | |
| SCHEMBL287202 | 0.82 | SLC18A3 (0.48) | SLC18A3TRPV1CD44 | |
| SCHEMBL5243506 | 0.82 | SLC18A3 (0.48) | SLC18A3TRPV1CD44 | |
| SCHEMBL12540413 | 0.82 | SLC18A3 (0.48) | SLC18A3TRPV1CD44 | |
| SCHEMBL4813078 | 0.79 | CHRM3 (0.65) | CHRM3CHRM2CHRM1 | |
| SCHEMBL23045121 | 0.78 | TRPV1 (0.45) | CHRM3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-118812481-A | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-4410989-A2 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4019485-B1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-114206847-B | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206847-A | Process for producing heterocyclylideneacetamide derivative | 持田制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1670761-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040119-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | SLC18A3 578/4885CHRM3 318/4885TRPV1 1/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | SLC18A3 3487/4885CHRM3 2948/4885TRPV1 3997/4885 |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | COASY, NAAA, AADAC | SLC18A3 4071/4885CHRM3 4463/4885TRPV1 2623/4885 |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | SLC18A3 4071/4885CHRM3 4463/4885TRPV1 2623/4885 |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | NMUR1, HVCN1, GPR17 | SLC18A3 437/4885CHRM3 695/4885TRPV1 18/4885 |
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | SLC18A3 4071/4885CHRM3 4463/4885TRPV1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.